Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
VRDN(NASDAQ:VRDN) WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively. VRDN-003 is a subcutaneously delivered, half-life extended, monoclonal antibody targeting the insulin-like growth fa
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN(NASDAQ:VRDN) WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 139,600 shares of the company’s common stock to 4 new employees (th
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
VRDNWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Veligrotug’s recent Breakthrough Therapy Designation as well as the continued and consistent performance of veligrotug across all of the endpoints and timepoints in our
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDNWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 181,450 shares of the company’s common stock to 4 new employees (th
Needham Reiterates Buy on Viridian Therapeutics, Maintains $36 Price Target
VRDNViridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients
VRDNWhat 5 Analyst Ratings Have To Say About Viridian Therapeutics
VRDNViridian Therapeutics Receives FDA Breakthrough Therapy Designation For Veligrotug For Thyroid Eye Disease
VRDNRBC Capital Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $45
VRDNGoldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27
VRDNJMP Securities Maintains Market Outperform on Viridian Therapeutics, Lowers Price Target to $38
VRDNNeedham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $36
VRDNViridian Therapeutics Q1 EPS $(0.87) Beats $(1.01) Estimate, Sales $72.00K Beat $70.13K Estimate
VRDNHC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target
VRDNViridian Therapeutics Appoints Seth Harmon As CFO
VRDNWells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target
VRDNHC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $34
VRDNViridian Therapeutics Files For Mixed-Securities Shelf Offering, Size Not Disclosed
VRDNViridian Therapeutics Earnings Perspective: Return On Capital Employed
VRDNBenzinga Pro data, Viridian Therapeutics (NASDAQ:VRDN) reported Q2 sales of $256 thousand. Earnings fell to a loss of $29.49 million, resulting in a 14.78% decrease from last quarter.
